At the First Academic Symposium on the Development of the Precision Manufacturing Industry and the Announcement Ceremony for BMF Precision Tech's RMB 170 Million D-Round Funding held on the 30th, bioGenous and BMF Precision Tech jointly unveiled the first research and development achievement of their strategic partnership: a significant centimeter-scale tumor organoid technological breakthrough.

The bioreactor produced using high-precision 3D printing technology features 100-micrometer tube walls and capillary-like network structures with perfusion holes below 5 micrometers, combined with a digital perfusion system. This completely resolves the technical challenges of insufficient internal nutrition supply and difficulty in removing metabolic waste during the long-term culture of classic 3D tumor organoids.

This innovative technology has achieved "centimeter-scale tumor mimics," significantly enhancing the size, lineage complexity, and regional heterogeneity of tumor cultures in vitro, making them closer to real tumors in patients and exhibiting more clinically consistent drug sensitivity. This provides a "hyper-biomimetic and standardized" model platform for the development of new tumor drugs. With more biomimetic organ sizes, more complex lineage synergies, and more precise drug evaluations, this will practically promote a significant extension of organoid technology in both temporal and spatial dimensions, bridging the "last mile" for organoid technology to replace animal models.

The academicians HOU Li'an, GE Changchun, ZHU Meifang, LIU Wenqing, PAN Fusheng, LI Jinghong, YU Shuhong, ZHANG Ping, TAN Jianrong, YU Aibing, ZHANG Qin, and ZHANG Jing'an, who attended this academic seminar, listened to the technical report and paid significant attention to it. They evaluated this technology as a "deep integration of precision printing and cutting-edge biotechnology" that "will establish more biomimetic and precise models for the development of antitumor drugs."

Both bioGenous and BMF Precision have applied for intellectual property protection for this original technology and are jointly promoting its productization and service launch. We welcome inquiries and cooperation from interested parties.